» Articles » PMID: 15755325

Patient-reported Outcome and Quality of Life Instruments Database (PROQOLID): Frequently Asked Questions

Overview
Publisher Biomed Central
Specialty Public Health
Date 2005 Mar 10
PMID 15755325
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The exponential development of Patient-Reported Outcomes (PRO) measures in clinical research has led to the creation of the Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID) to facilitate the selection process of PRO measures in clinical research. The project was initiated by Mapi Research Trust in Lyon, France. Initially called QOLID (Quality of Life Instruments Database), the project's purpose was to provide all those involved in health care evaluation with a comprehensive and unique source of information on PRO and HRQOL measures available through the Internet.PROQOLID currently describes more than 470 PRO instruments in a structured format. It is available in two levels, non-subscribers and subscribers, at http://www.proqolid.org. The first level is free of charge and contains 14 categories of basic useful information on the instruments (e.g. author, objective, original language, list of existing translations, etc.). The second level provides significantly more information about the instruments. It includes review copies of over 350 original instruments, 120 user manuals and 350 translations. Most are available in PDF format. This level is only accessible to annual subscribers. PROQOLID is updated in close collaboration with the instruments' authors on a regular basis. Fifty or more new instruments are added to the database annually.Today, all of the major pharmaceutical companies, prestigious institutions (such as the FDA, the NIH's National Cancer Institute, the U.S. Veterans Administration), dozens of universities, public institutions and researchers subscribe to PROQOLID on a yearly basis. More than 800 users per day routinely visit the database.

Citing Articles

Language understanding and preferences when reporting symptoms for pediatric patients receiving cancer treatments and their guardians.

Mehrdadi I, Joseph-Frederick Z, Petrazzini A, Apolot J, Roshdi A, Dhaliwal N Support Care Cancer. 2025; 33(3):233.

PMID: 40016500 DOI: 10.1007/s00520-025-09296-x.


Development of a Patient-Reported Symptom Item Bank for Patients with Hepatobiliary or Pancreatic Malignancies: A Systematic Review.

Zhang J, Zhan Y, Chen J, Kang D, Xiang R, Zhang R Patient Prefer Adherence. 2023; 17:199-207.

PMID: 36698859 PMC: 9869794. DOI: 10.2147/PPA.S398666.


Characteristics and quality of life of substance users and their caregivers.

Maksimovic J, Sbutega O, Pavlovic A, Vlajinac H, Kavecan I, Vujcic I Medicine (Baltimore). 2022; 101(31):e29699.

PMID: 35945774 PMC: 9351891. DOI: 10.1097/MD.0000000000029699.


Development and Validation of the Breast Cancer Scale QLICP-BR V2.0 Based on Classical Test Theory and Generalizability Theory.

Li F, Zhou J, Wan C, Yang Z, Liang Q, Li W Front Oncol. 2022; 12:915103.

PMID: 35769719 PMC: 9235398. DOI: 10.3389/fonc.2022.915103.


Perceptions of the General Public About Health-related Quality of Life and the EQ-5D Questionnaire: A Qualitative Study in Korea.

Ock M, Pyo J, Jo M, Herdman M, Luo N J Prev Med Public Health. 2022; 55(3):213-225.

PMID: 35677995 PMC: 9201084. DOI: 10.3961/jpmph.22.151.


References
1.
Bolling-Sternevald E, Lauritsen K, Talley N, Junghard O, Glise H . Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?. Aliment Pharmacol Ther. 2003; 18(1):117-24. DOI: 10.1046/j.1365-2036.2003.01651.x. View

2.
Leidy N, Revicki D, Geneste B . Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 2006; 2(2):113-27. DOI: 10.1046/j.1524-4733.1999.02210.x. View

3.
Muller-Buhl U, Engeser P, Klimm H, Wiesemann A . Quality of life and objective disease criteria in patients with intermittent claudication in general practice. Fam Pract. 2003; 20(1):36-40. DOI: 10.1093/fampra/20.1.36. View

4.
Willke R, Burke L, Erickson P . Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2004; 25(6):535-52. DOI: 10.1016/j.cct.2004.09.003. View

5.
Acquadro C, Berzon R, Dubois D, Leidy N, Marquis P, Revicki D . Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003; 6(5):522-31. DOI: 10.1046/j.1524-4733.2003.65309.x. View